310 related articles for article (PubMed ID: 29175369)
1. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria.
Straesser MD; Oliver E; Palacios T; Kyin T; Patrie J; Borish L; Saini SS; Lawrence MG
J Allergy Clin Immunol Pract; 2018; 6(4):1386-1388.e1. PubMed ID: 29175369
[No Abstract] [Full Text] [Related]
2. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
[No Abstract] [Full Text] [Related]
3. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria.
Ertas R; Ozyurt K; Ozlu E; Ulas Y; Avci A; Atasoy M; Hawro T; Maurer M
J Allergy Clin Immunol; 2017 Dec; 140(6):1749-1751. PubMed ID: 28870460
[No Abstract] [Full Text] [Related]
4. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab.
Weller K; Ohanyan T; Hawro T; Ellrich A; Sussman G; Koplowitz J; Gimenez-Arnau AM; Peveling-Oberhag A; Staubach P; Metz M; Maurer M
Allergy; 2018 Dec; 73(12):2406-2408. PubMed ID: 30076605
[No Abstract] [Full Text] [Related]
5. Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria.
Cugno M; Asero R; Ferrucci S; Lorini M; Carbonelli V; Tedeschi A; Marzano AV
Allergy; 2018 Dec; 73(12):2408-2411. PubMed ID: 30076634
[No Abstract] [Full Text] [Related]
6. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria.
Palacios T; Stillman L; Borish L; Lawrence M
J Allergy Clin Immunol Pract; 2016; 4(3):529-30. PubMed ID: 26725153
[No Abstract] [Full Text] [Related]
7. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
9. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
[TBL] [Abstract][Full Text] [Related]
10. Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU.
Asero R; Marzano AV; Ferrucci S; Cugno M
J Allergy Clin Immunol Pract; 2017; 5(6):1740-1742. PubMed ID: 28866106
[No Abstract] [Full Text] [Related]
11. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
12. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria.
Koski R; Kennedy KK
Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066
[No Abstract] [Full Text] [Related]
13. Combining Omalizumab with Another Biotherapy.
Fougerousse AC; Becherel PA; Pallure V; Boyé T; Reguiai Z; Gabison G; Barthelemy H; Badaoui A; Mahé E; Livideanu CB;
Acta Derm Venereol; 2019 Apr; 99(4):448-449. PubMed ID: 30723874
[No Abstract] [Full Text] [Related]
14. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
Skander D; Allenova A; Maurer M; Kolkhir P
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
[No Abstract] [Full Text] [Related]
16. Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug.
Asero R
Allergy; 2018 Nov; 73(11):2242-2244. PubMed ID: 29989179
[No Abstract] [Full Text] [Related]
17. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
18. Basophil count is a sensitive marker for clinical progression in a chronic spontaneous urticaria patient treated with omalizumab.
Kishimoto I; Kambe N; Ly NTM; Nguyen CTH; Okamoto H
Allergol Int; 2019 Jul; 68(3):388-390. PubMed ID: 30792119
[No Abstract] [Full Text] [Related]
19. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
